Brief: Heidelberg Pharma And Huadong Announce Strategic Partnership

Heidelberg Pharma AG

28/02/2022 06:06

Feb 28 (Reuters) - HEIDELBERG PHARMA AG  HPHA.DE :
    * HEIDELBERG PHARMA AND HUADONG ANNOUNCE STRATEGIC
PARTNERSHIP,
INCLUDING EQUITY INVESTMENT
    * HEIDELBERG PHARMA GRANTS HUADONG EXCLUSIVE LICENSE TO
DEVELOP
AND COMMERCIALIZE HDP-101 AND HDP-103 IN ASIA 1  (EXCLUDING
JAPAN), PLUS EXCLUSIVE OPT-IN RIGHTS FOR TWO MORE PIPELINE
CANDIDATES, WITH A TOTAL DEAL VALUE OF UP TO USD 930 MILLION
    * HUADONG WILL ALSO PARTICIPATE IN A RIGHTS ISSUE AND
ACQUIRE A
PERCENTAGE OF CURRENT SHAREHOLDINGS FROM EXISTING SHAREHOLDERS
INCLUDING DIEVINI^ 2  2 , TOTALING EUR 105 MILLION
    * HEIDELBERG PHARMA PLANS RIGHTS ISSUE OF UP TO EUR 80
MILLION AT
EUR 6.44 PER SHARE
    * HEIDELBERG PHARMA PLANS RIGHTS ISSUE OF UP TO EUR 80
MILLION AT
EUR 6.44 PER SHARE
    * HUADONG TO BECOME SECOND LARGEST SHAREHOLDER; DIEVINI
REMAINS
LARGEST SHAREHOLDER

Source text for Eikon:  ID:nEQ2LlVkJa 
Further company coverage:  HPHA.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))